Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174225 | 0.83 | RIPK2 (0.51) | ALDH1A1TDP1KDM4ENPC1RAB9A | |
| SCHEMBL535661 | 0.83 | KDM4E (0.44) | ALDH1A1TDP1KDM4ENPC1RAB9A | |
| SCHEMBL27714949 | 0.82 | PROKR1 (0.39) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9921391 | 0.80 | POLB (0.39) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3436120 | 0.79 | CYP1A2 (0.51) | ALDH1A1TDP1KDM4ENPC1RAB9A | |
| SCHEMBL22336048 | 0.79 | RAB9A (0.39) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2061609 | 0.79 | MAPK14 (0.44) | ALDH1A1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL10452886 | 0.79 | PROKR1 (0.35) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1641560 | 0.77 | SMN1; SMN2 (0.54) | MAPK1ALDH1A1TDP1KDM4ENPC1 | |
| SCHEMBL21938820 | 0.77 | MAPK1 (0.41) | MAPK1ALDH1A1TDP1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151550-B | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2024-11-22 | — | — | CN | disclosed |
| WO-2021133915-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2020161208-A1 | HERBICIDAL FUSED PYRIDAZINE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2020-08-13 | — | — | WO | disclosed |
| WO-2018033082-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-02-22 | — | — | WO | disclosed |
| US-8580838-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2013-11-12 | — | — | US | disclosed |
| US-20130172352-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8410160-B2 | 5-membered heterocycle-based P38 kinase inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120264801-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-8242117-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| US-20110071152-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MEREO BIOPHARMA 1 LIMINTED (GB) | 2011-03-24 | — | — | US | disclosed |
| US-7863314-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2011-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172352-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | MAPK1 1/4885ALDH1A1 2270/4885TDP1 1070/4885 |
| US-20120264801-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | MAPK1 1/4885ALDH1A1 2270/4885TDP1 1070/4885 |
| US-20110071152-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | MAPK1 1/4885ALDH1A1 2142/4885TDP1 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.